Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial reveals improved survival with perioperative chemotherapy in gastroesophageal adenocarcinoma, highlighting the benefit of systemic treatment around surgery.
Key Points
- To assess whether perioperative chemotherapy improves curative resection rates and survival compared with surgery alone in patients with resectable gastroesophageal adenocarcinoma.
- Multicenter phase III randomized trial conducted by the FNCLCC and FFCD.
- Enrolled patients with resectable adenocarcinoma located in the lower esophagus, gastroesophageal junction, or stomach.
- Evaluated perioperative fluorouracil plus cisplatin combined with surgery versus surgery alone.
- Perioperative chemotherapy significantly improved the curative resection rate compared with surgery alone.
- Patients receiving perioperative fluorouracil plus cisplatin demonstrated significantly prolonged disease-free survival and overall survival.
Cite This Study
Ychou et al. (2011) studied this question.